Fenofibrate and Tecentriq drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Fenofibrate (fenofibrate) and Tecentriq (atezolizumab). Common drug interactions include arthralgia among males.

The phase IV clinical study analyzes what interactions people have when they take Fenofibrate and Tecentriq. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Fenofibrate?

Fenofibrate has active ingredients of fenofibrate. It is often used in high blood cholesterol. eHealthMe is studying from 40,457 Fenofibrate users. Check the latest studies of Fenofibrate.

What is Tecentriq?

Tecentriq has active ingredients of atezolizumab. eHealthMe is studying from 12,796 Tecentriq users. Check the latest studies of Tecentriq.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

11 people who take Fenofibrate and Tecentriq together, and have interactions are studied.

Fenofibrate and Tecentriq drug interactions.

What are the common drug interactions of Fenofibrate and Tecentriq, by gender? *:

female:

n/a

male:

Arthralgia (joint pain)
Back pain
Psoriasis (immune-mediated disease that affects the skin)
Pulmonary embolism (blockage of the main artery of the lung)
Appendicitis perforated (perforated appendicitis is a condition in which an inflamed appendix bursts)
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Large intestine perforation (hole in large intestine)
Neutropenia (an abnormally low number of neutrophils)
Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
Wound complication

What are the common drug interactions of Fenofibrate and Tecentriq, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Arthralgia (joint pain)
Back pain
Blood pressure increased
Constipation
Cough
Dizziness
Dysphonia (speech disorder attributable to a disorder of phonation)
Nausea (feeling of having an urge to vomit)
Prostatic specific antigen increased

60+:

Sepsis (a severe blood infection that can lead to organ failure and death)
Psoriasis (immune-mediated disease that affects the skin)
Device occlusion
Device related infection
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Hepatocellular carcinoma (liver cancer)
Hydronephrosis (water inside the kidney)
Liver abscess (pus in liver)
Peptic ulcer

What are the existing conditions these people have? *

Hepatocellular Carcinoma (liver cancer): 6 people, 54.55%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 2 people, 18.18%
Rickets (softening of bones): 2 people, 18.18%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 2 people, 18.18%
Lung Cancer - Small Cell (lung cancer): 2 people, 18.18%
Type 2 Diabetes: 2 people, 18.18%
Metastases To Bone (cancer spreads to bone): 1 person, 9.09%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 9.09%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 9.09%
Metastases To Bladder (cancer spreads to bladder): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Fenofibrate and Tecentriq?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously